1. European Monitoring Centre for Drug and Drug Addiction.European Drug Report2019: Trends and Developments. 2019. Available from:http://www.emcdda.europa.eu/system/files/publications/11364/20191724_TDAT19001ENN_PDF.pdf(last accessed 7thJanuary 2020)
2. European Monitoring Centre for Drug and Drug Addiction. EMCDDA Risk Assessments:Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances.2011. Available from:http://www.emcdda.europa.eu/system/files/publications/571/TDAK11001ENC_WEB-OPTIMISED_FILE_280269.pdf(last accessed 7thJanuary 2020)
3. United Nations Office on Drugs and Crime.Treaties: Drug‐related Treaties.2019. Available from:https://www.unodc.org/unodc/en/treaties/(last accessed 7thJanuary 2020)
4. Council of the European Union.Council Decision of 2 December 2010 on submitting 4‐methylmethcathinone (mephedrone) to control measures (2010/759/EU).2010. Official Journal of the European Union. 2010; 322(8.12.2010): 44–45. Available from:https://eur-lex.europa.eu/eli/dec/2010/759/oj(last accessed 7thJanuary 2020)
5. How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe